Figure 29.21
 Primary endpoint (stroke, systemic
embolus, myocardial infarction and vascular death in the ACTIVE W Study
comparing oral anticoagulation with warfarin against a fixed dose of
clopidogrel and aspirin (A). The occurrence of major bleeding (B). ASA,
aspirin; OAC, oral anticoagulation. Modified with permission from Connolly
S, Pogue J, Hart R, et al.; ACTIVE Writing Group on behalf of the
ACTIVE Investigators. Clopidogrel plus aspirin versus oral anticoagulation
for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with
Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised
controlled trial. Lancet 2006; 367: 1903–12.

Primary endpoint (stroke, systemic embolus, myocardial infarction and vascular death in the ACTIVE W Study comparing oral anticoagulation with warfarin against a fixed dose of clopidogrel and aspirin (A). The occurrence of major bleeding (B). ASA, aspirin; OAC, oral anticoagulation. Modified with permission from Connolly S, Pogue J, Hart R, et al.; ACTIVE Writing Group on behalf of the ACTIVE Investigators. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet 2006; 367: 1903–12.

Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close